Monoclonal antibodies targeting PD-1/PD-L1 and CTLA-4 have proven to be valuable tools for overcoming the inhibitory regulation of T-cell activation imposed by tumor cells or the tumor microenvironment (TME) [29]. This evidence concerns the gene RPL17 and neoplasm.